Shawn Hingtgen

4.5k total citations · 1 hit paper
69 papers, 3.4k citations indexed

About

Shawn Hingtgen is a scholar working on Genetics, Molecular Biology and Biomedical Engineering. According to data from OpenAlex, Shawn Hingtgen has authored 69 papers receiving a total of 3.4k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Genetics, 27 papers in Molecular Biology and 21 papers in Biomedical Engineering. Recurrent topics in Shawn Hingtgen's work include Glioma Diagnosis and Treatment (26 papers), Neurogenesis and neuroplasticity mechanisms (15 papers) and RNA Interference and Gene Delivery (12 papers). Shawn Hingtgen is often cited by papers focused on Glioma Diagnosis and Treatment (26 papers), Neurogenesis and neuroplasticity mechanisms (15 papers) and RNA Interference and Gene Delivery (12 papers). Shawn Hingtgen collaborates with scholars based in United States, United Kingdom and Czechia. Shawn Hingtgen's co-authors include Khalid Shah, Onyi Okolie, Alexander V. Kabanov, José Luiz de Figueiredo, Elena V. Batrakova, Vivek Mahajan, Matthew J. Haney, Natalia L. Klyachko, Yuling Zhao and Marina Sokolsky‐Papkov and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Neuroscience.

In The Last Decade

Shawn Hingtgen

64 papers receiving 3.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Development of exosome-encapsulated paclitaxel to overcome MDR in cancer cells

2015 1.2k citations Marina Sokolsky‐Papkov, Shawn Hingtgen et al. profile →

Peers

Countries citing papers authored by Shawn Hingtgen

Since Specialization

Citations

This map shows the geographic impact of Shawn Hingtgen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shawn Hingtgen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shawn Hingtgen more than expected).

Fields of papers citing papers by Shawn Hingtgen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shawn Hingtgen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shawn Hingtgen. The network helps show where Shawn Hingtgen may publish in the future.

Co-authorship network of co-authors of Shawn Hingtgen

This figure shows the co-authorship network connecting the top 25 collaborators of Shawn Hingtgen. A scholar is included among the top collaborators of Shawn Hingtgen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shawn Hingtgen. Shawn Hingtgen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Exosomes: Traversing the blood-brain barrier and their therapeutic potential in brain cancer 2025 ·Biochimica et Biophysica Acta (BBA) - Reviews on Cancer ·Xiaopei Zhang, (unknown), Dennis A. Steindler, Shawn Hingtgen, Andrew Satterlee	6
2	Repurposing the DNA Labeling Agent EdU for Therapy against Heterogeneous Patient Glioblastoma 2025 ·Molecular Cancer Therapeutics ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Noah Bell, Stephen T. Keir, Dominique Higgins, David E. Kram, Shawn Hingtgen, Aziz Sancar, Andrew Satterlee	1
3	Opportunities and challenges for patient-derived models of brain tumors in functional precision medicine 2025 ·npj Precision Oncology ·(unknown), (unknown), (unknown), David E. Kram, Shawn Hingtgen, Andrew Satterlee	7
4	Characterization of a Bioprinted Anticancer Cell Therapy System Generated with Continuous Liquid Interface Production 2025 ·Advanced NanoBiomed Research ·(unknown), (unknown), (unknown), J. Fraser Forbes, (unknown), Jillian L. Perry, Shawn Hingtgen	0
5	Post-resection delivery of a TLR7/8 agonist from a biodegradable scaffold achieves immune-mediated glioblastoma clearance and protection against tumor challenge in mice 2025 ·Nature Communications ·Elizabeth G. Graham-Gurysh, (unknown), (unknown), (unknown), (unknown), (unknown), Kathryn M. Moore, (unknown), (unknown), (unknown), (unknown), (unknown), Christopher J. Genito, (unknown), (unknown), William C. Zamboni, Shawn Hingtgen, Peter E. Fecci, Eric M. Bachelder, Kristy M. Ainslie	0
6	Development of a biocompatible 3D hydrogel scaffold using continuous liquid interface production for the delivery of cell therapies to treat recurrent glioblastoma 2024 ·Bioengineering & Translational Medicine ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Jillian L. Perry, Shawn Hingtgen	3
7	Magnetic Control of Protein Expression via Magneto-mechanical Actuation of ND-PEGylated Iron Oxide Nanocubes for Cell Therapy 2023 ·ACS Applied Materials & Interfaces ·Juan Beltran‐Huarac, (unknown), Gianpietro Dotti, Shawn Hingtgen, Marina Sokolsky‐Papkov, Alexander V. Kabanov	13
8	Utilizing induced neural stem cell‐based delivery of a cytokine cocktail to enhance chimeric antigen receptor‐modified T‐cell therapy for brain cancer 2023 ·Bioengineering & Translational Medicine ·(unknown), Elisa Landoni, (unknown), Andrew Buckley, Edikan A. Ogunnaike, Gianpietro Dotti, Shawn Hingtgen	4
9	Current approaches in enhancing TRAIL therapies in glioblastoma 2023 ·Neuro-Oncology Advances ·(unknown), (unknown), (unknown), Phuong L. Nguyen, Shawn Hingtgen	11
10	Cytotoxic Engineered Induced Neural Stem Cells as an Intravenous Therapy for Primary Non–Small Cell Lung Cancer and Triple-Negative Breast Cancer 2021 ·Molecular Cancer Therapeutics ·(unknown), (unknown), Juli R. Bagó, (unknown), (unknown), (unknown), Stephanie A. Montgomery, Kevin Sheets, Carey K. Anders, Shawn Hingtgen	2
11	Use of FLOSEAL ® as a scaffold and its impact on induced neural stem cell phenotype, persistence, and efficacy 2021 ·Bioengineering & Translational Medicine ·Hunter N. Bomba, (unknown), Kevin Sheets, (unknown), Morgan Goetz, (unknown), (unknown), (unknown), Simon Khagi, Shawn Hingtgen	7
12	Tumor Responsive and Tunable Polymeric Platform for Optimized Delivery of Paclitaxel to Treat Glioblastoma 2020 ·ACS Applied Materials & Interfaces ·Elizabeth G. Graham-Gurysh, Kathryn M. Moore, Allison N. Schorzman, Taek Lee, William C. Zamboni, Shawn Hingtgen, Eric M. Bachelder, Kristy M. Ainslie	43
13	Polymeric Biomaterial Scaffolds for Tumoricidal Stem Cell Glioblastoma Therapy 2020 ·ACS Biomaterials Science & Engineering ·Kathryn M. Moore, (unknown), Elizabeth G. Graham-Gurysh, Shawn Hingtgen, Eric M. Bachelder, Kristy M. Ainslie	17
14	Developing Bioinspired Three-Dimensional Models of Brain Cancer to Evaluate Tumor-Homing Neural Stem Cell Therapy 2020 ·Tissue Engineering Part A ·(unknown), (unknown), Hunter N. Bomba, (unknown), Juli R. Bagó, Shawn Hingtgen	13
15	Development and in vivo evaluation of Irinotecan-loaded Drug Eluting Seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme 2020 ·Journal of Controlled Release ·(unknown), (unknown), (unknown), (unknown), (unknown), A. Detta, Garth Cruickshank, C. Ryan Miller, Shawn Hingtgen, Kevin Sheets, Christopher McConville	14
16	Sustained Delivery of Doxorubicin via Acetalated Dextran Scaffold Prevents Glioblastoma Recurrence after Surgical Resection 2018 ·Molecular Pharmaceutics ·Elizabeth G. Graham-Gurysh, Kathryn M. Moore, Andrew Satterlee, Kevin Sheets, Feng‐Chang Lin, Eric M. Bachelder, C. Ryan Miller, Shawn Hingtgen, Kristy M. Ainslie	50
17	Real-time multi-modality imaging of glioblastoma tumor resection and recurrence 2012 ·Journal of Neuro-Oncology ·Shawn Hingtgen, José Luiz de Figueiredo, Christian T. Farrar, (unknown), Jordi Martínez‐Quintanilla, Deepak Bhere, Khalid Shah	48
18	Bimodal Viral Vectors andIn VivoImaging Reveal the Fate of Human Neural Stem Cells in Experimental Glioma Model 2008 ·Journal of Neuroscience ·Khalid Shah, Shawn Hingtgen, Randa Kasmieh, José Luiz de Figueiredo, (unknown), Alberto Martínez‐Serrano, Xandra O. Breakefield, Ralph Weissleder	76
19	Visualizing the Dynamics of EGFR Activity and Antiglioma Therapies In vivo 2007 ·Cancer Research ·Esther N. Arwert, Shawn Hingtgen, José Luiz de Figueiredo, (unknown), Umar Mahmood, Ralph Weissleder, Khalid Shah	32
20	Gene Therapeutic Approaches to Oxidative Stress-Induced Cardiac Disease: Principles, Progress, and Prospects 2001 ·Antioxidants and Redox Signaling ·Shawn Hingtgen, Robin L. Davisson	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact